ONCOSIL MEDICAL LTD — Capital/Financing Update 2025

Jul 6, 2025

ASX Announcement

==> picture [129 x 31] intentionally omitted <==

7 July 2025

OncoSil completes on strongly supported and oversubscribed $2 million Share Purchase Plan

OncoSil Medical Ltd (ASX: OSL) (the Company, OncoSil or OSL ) confirms that the Share Purchase Plan ( SPP ) announced on 26 May 2025, closed on 4 July 2025 (Closing Date).

The Company is pleased to report that participation in the SPP was strongly supported and oversubscribed by eligible shareholders. OncoSil Medical received total valid applications for approximately $4.5 million, or approximately $2.5 million in oversubscriptions. The Company has resolved to scale back applications and accept $2.0 million, which is the maximum contained in the SPP Prospectus issued on 26 May 2025 (Prospectus). Approval for the SPP is to be considered by shareholders at the the Extraordinary General Meeting to be held tomorrow, Tuesday 8 July 2025.

• Under the Prospectus dated 26 May 2025, the SPP Issue Price per New Share is the lower of i. $1.20 (on a post-consolidation basis); and

• ii. a 2.5% discount to the 5-day VWAP at the Closing Date of the SPP Offer (SPP Issue Price).

The 5-day VWAP at the Closing Date of the SPP Offer was $1.188, and a 2.5% discount to the 5-day VWAP is $1.158. Consequently, the SPP Issue price is $1.158 per New Share. The issue of shares and options under the SPP is subject to shareholder approval at the Extraordinary General Meeting to be held tomorrow, Tuesday 8 July 2025.

Subject to shareholder approval, it is anticipated that approx. 1.7 million New Shares and approx. 1.7 million New Options will be issued under the SPP Offer. The New Options are exercisable at any time until and including their expiry date of 31 July 2027 at an exercise price of $1.20 each. The Company will apply for the New Options to be quoted on ASX. The New Shares and New Options are due to be issued on 11 July 2025, and to commence trading on or around 14 July 2025.

The funds raised from the SPP will be applied to further investment in OncoSil Medical's Macquarie Park manufacturing facility, funding of clinical trials, together with payment for other working capital costs and costs of the offer.

Managing Director and CEO, Nigel Lange said: “We would like to thank our shareholders for their continued support in OncoSil. The SPP raise enables us to focus our efforts on commercial activities, completing important clinical trials that enable label expansion and permit increased market access. OncoSil remains focused on its cost-out initiatives to drive a lower fixed cost base with significant opportunity for operating leverage. Additionally, OSL is wellfunded until 2H CY26, where cashflow breakeven is targeted during this period”

A term not defined in this ASX Announcement has the same meaning as given to it in the Prospectus.

Indicative SPP Offer Timetable1	Date
	2025
Extraordinary General Meeting to consider the issue of shares and options under the SPP Offer	8 July
Issue of New Shares and Options under SPP Offer	11 July
Expected normal trading of New Shares and Options under SPP Offer	14 July

1. Dates / times are indicative and subject to change. All times / dates are in reference to AEST.

Authorisation & Additional Information

This announcement was authorised by the Chairman of OncoSil Medical Limited.

For further information, please contact:

	Mr. Nigel Lange CEO & Managing Director E:nigel.lange@oncosil.com T: +49 30 300 149 3043	Mr. Nathan Jong Company Secretary E:Nathan.Jong@acclime.com T: +61 3 9864 4810	Ms. Julia Maguire The Capital Network Media and Investor Enquiries E:julia@thecapitalnetwork.com.au T: +61 2 8999 3699

About OncoSil Medical

OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12[th] most common cancer in men and the 11[th] most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for long-term survival[1] .

The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 ([32] P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient’s pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy.

The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.

While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.

To learn more, please visit: www.oncosil.com/

References: 1. https://www.wcrf.org/cancer-trends/pancreatic-cancer-statistics/